about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Hun­ker­ing down on deals and racial di­ver­si­ty pledge amid pan­dem­ic, Gio­van­ni Caforio took home $20M last year at ...

5 years ago
People

Covid-19 roundup: Cuo­mo ad­min­is­tra­tion al­leged­ly gave Re­gen­eron's George Yan­copou­los spe­cial pref­er­ence for test­ing ...

5 years ago
Coronavirus

GV wa­gers on sea­soned team's in­tranasal 'tem­po­rary' pre­ven­ta­tive ap­proach to virus­es — with ex-Gilead CEO John ...

5 years ago
Financing
Startups

Neu­ro up­start launch­es out of RA Cap­i­tal’s low-pro­file in­cu­ba­tor with Big Phar­ma vets, clin­i­cal drugs and $80M

5 years ago
Financing
Startups

Pfiz­er emerges from pan­dem­ic cru­cible with con­fi­dence to go so­lo in tak­ing mR­NA vac­cines be­yond Covid-19

5 years ago
Pharma
Coronavirus

Hear­ing loss spe­cial­ists at Fre­quen­cy pin the blame for PhI­Ia flop on tri­al de­sign — but they could­n't stem a ...

5 years ago
R&D

Trans-Pa­cif­ic bis­pe­cif­ic play­er caps 'very chal­leng­ing' pan­dem­ic year with $120M to gain a foothold among the gi­ants

5 years ago
China

As­traZeneca read­ies April EUA fil­ing with 79% vac­cine ef­fi­ca­cy, first glimpse of el­der­ly da­ta and 100% pro­tec­tion ...

5 years ago
R&D
Coronavirus

Mer­ck­'s C-suite shake­up, Eli Lil­ly stirs fresh Alzheimer's con­tro­very, play by play of Am­gen's $2B buy­out, and more

5 years ago
Weekly

Jakafi failed the pri­ma­ry end­point in a Covid-19 study. But In­cyte is still go­ing to FDA with a com­pas­sion­ate use ...

5 years ago
R&D
Coronavirus

Are ra­dio­phar­ma­ceu­ti­cals ready for the main­stream? No­var­tis, Bris­tol My­ers Squibb bet yes on MP­M's plat­form take

5 years ago
Financing

Got a rev­o­lu­tion­ary health­care com­pa­ny? Bob Nelsen, Jeff Lei­den’s SPAC has $500M to take it pub­lic

5 years ago
Financing

Af­ter a roller coast­er ride, Sage COO strikes out on his own to chart a new biotech path

5 years ago
People

Eli Lil­ly, No­var­tis back a biotech start­up boast­ing 'best of both world­s' pro­tein de­graders

5 years ago
Financing

With all the buzz in gene ther­a­py, Sanofi of­floads two small mol­e­cule sick­le cell pro­grams from $11.6B buy­out to ...

5 years ago
Deals

Take­da, Sarep­ta dou­ble down on a biotech part­ner's plat­form to en­gi­neer bet­ter AAV cap­sids by map­ping out their ...

5 years ago
Financing
Cell/Gene Tx

No quick re­demp­tion for Glax­o­SmithK­line’s $4B al­liance with Mer­ck KGaA as bis­pe­cif­ic can­cer drug flunks a sec­ond ...

5 years ago
R&D

Sol­id Bio’s long, trou­bled slog through the clin­ic yields 'en­cour­ag­ing' ear­ly da­ta and no new safe­ty con­cerns. It's ...

5 years ago
R&D
Cell/Gene Tx

Daphne Koller lines up $400M for a glob­al shop­ping spree to vault for­ward on AI drug dis­cov­ery

5 years ago
Financing
AI

Covid-19 roundup: Ger­many sus­pends As­traZeneca vac­cine as British drug­mak­er de­fends shot amid blood clot scare

5 years ago
Coronavirus

On a roll, Re­gen­eron and Sanofi boast pos­i­tive PhI­II OS re­sults in 'no­to­ri­ous­ly' tough can­cer

5 years ago
R&D
Pharma

No­var­tis' wild card block­buster con­tender falls flat; Reg­u­la­to­ry reck­on­ing for check­point drugs looms; and more

5 years ago
Weekly

Covid-19 roundup: As­traZeneca cuts Q1 vac­cine sup­ply to EU by a third — re­port; Sanofi, Trans­late ush­er an­oth­er ...

5 years ago
Coronavirus

Covid-19 roundup: Pfiz­er/BioN­Tech re­lease re­al-world ev­i­dence of vac­cine ef­fi­ca­cy; EMA gives J&J shot thumbs up

5 years ago
Coronavirus
First page Previous page 53545556575859 Next page Last page
A service from the Financial Times